Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6286 | Ordered by Date (descending)
1 2 3 ... 61 62 63  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Kiadis–Leucadia: investor conference, 201906 supply service Kiadis presents at Jefferies 2019 Global Healthcare Conference NYC 2019-06-04
Bruker Corp–PreOmics: sample preparation technology, 201905– collab developm + marketing PreOmics iST sample preparation on timsTOF Pro MS system 2019-05-31
Medical Univ South Carolina–Bruker Corp: mass spectrometer, 201905 supply existent timsTOF fleX system early customer Proteomics Center at Med Univ SC 2019-05-31
Kiadis–SEVERAL: investment, 201905 private placment €27.6m with 3.68m new shares at €7.5/share 2019-05-30
Bayer–Roche: molecular companion diagnostics, 201905– collab ww €na developm + commercialisation o fNGS-based CDx in oncology 2019-05-29
Cubuslab–Labfolder: investment, 201905 acquisition merger of Cubuslab Gmbh + Labfolder GmbH + new name Labforward GmbH 2019-05-22
Kiadis–Be The Match: cell therapy, 201905– collab logistical + technological solutions for ATIR101 developm in US + CA by Be The Match 2019-05-22
JnJ–Owlstone: breath analyser, 201905– collab developm breath-based test for early detection of pulmonary hypertension with Actelion 2019-05-20
Just Biotherapeutics (US)–Evotec: investment, 201905– acquisition 100% for $60m upfront + $30m upfront 2019-05-20
LifeArc–CPPIB: pembrolizumab, 201905 acquisition of portion of Keytruda royalty interests for $1.297b by CPPIB Credit Europe Sàrl 2019-05-20
Storm Therapeutics–Pfizer: investment, 201905 financing round Series A extension totalling £14m incl existing investor Pfizer Ventures 2019-05-20
Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS 2019-05-20
Avantor–SEVERAL: investment, 201905 IPO $3.8b at NYSE with Avantor continuing to be largest shareholder 2019-05-17
LabCentral–Harrison Street: business park, 201905 supply service existent LabCentral is anchor tenant at Osborn Triangle lab complex in Cambridge MA 2019-05-17
MIT–Harrison Street: business park, 201905 acquisition of Osborn Triangle complex by Harrision Street + Bulfinch from MIT with MIT retaining interest 2019-05-17
Novartis–Harrison Street: business park, 201905 supply service existent Novartis 1 of 3 anchor tenants at Osborn Triangle lab complex in Cambridge MA 2019-05-17
Pfizer–Harrison Street: business park, 201905 supply service existent Pfizer is 1 of 3 anchor tenants at Osborn Triangle lab complex in Cambridge MA 2019-05-17
DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP 2019-05-16
Inovio–Qiagen: molecular companion diagnostics, 201905– collab developm of CDx for VGX-3100 DNA-based immunotherapy for cervical dysplasia 2019-05-16
Roche–AbbVie: ventoclax, 201905 collab existent joint commercialisation in US as Venclexta by AbbVie + Genentech 2019-05-16
Navan Technologies–Amgen: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al 2019-05-15
Navan Technologies–Hemi Ventures: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al 2019-05-15
Navan Technologies–High-Tech Gründerfonds: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al 2019-05-15
Navan Technologies–SEVERAL: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al 2019-05-15
Navan Technologies–Stanford Univ: cell therapy technology, 201905 license excl existent to NanoStraw technology platform 2019-05-15
Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders 2019-05-15
MabVax Therapeutics–BioNTech: investment, 201905 acquisition €na of antibody assets + infrastructure + lab equipment in San Diego 2019-05-08
Therachon–Cowen: investment, 201905 existing investor Cowen 2019-05-08
Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative 2019-05-08
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Therachon–OrbiMed: investment, 201905 existing investor OrbiMed 2019-05-08
Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures 2019-05-08
Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program 2019-05-08
Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC 2019-05-08
Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures 2019-05-08
Confo Therapeutics–Perceptive Advisors: investment, 201905 financing round Series A totalling €30m incl new + co-investor Perceptive Advisors 2019-05-07
Confo Therapeutics–SEVERAL: investment, 201905 financing round Series A €30m led by BGV + co-led by Wellington Partners 2019-05-07
Confo Therapeutics–Univ Michigan: investment, 201905 financing round Series A totalling €30m incl existing + co-investor MINTS 2019-05-07
Confo Therapeutics–V-Bio Ventures: investment, 201905 financing round Series A totalling €30m incl existing + co-investor V-Bio Ventures 2019-05-07
Confo Therapeutics–VIB: investment, 201905 financing round Series A totalling €30m incl existing + co-investor VIB 2019-05-07
Merck (DE)–DyNAbind: drug discovery technology, 201905 collab existent marketing of DEL discovery kit with Merck KGaA 2019-05-07
Northwestern Univ–DyNAbind: drug discovery technology, 201905 collab existent with Northwestern Univ Chicago 2019-05-07
Promethera–SEVERAL: investment, 201905 financing round Series D €39.7m co-led by Itochu Corp + Shinsei Capital Partners 2019-05-07
Promethera–Shinsei Capital: investment, 201905 financing round Series D totalling €39.7m incl new + co-lead investor Shinsei Capital Partners 2019-05-07
Abide Therapeutics–Lundbeck: investment, 201905– acquisition $250m upfront + $150m milestones of Abide by Lundbeck 2019-05-06
Chemical Solutions Ltd–SGS: investment, 201905 acquisition of CSL by SGS 2019-05-03
Diem Labs–Devicare: medical device, 201905– collab marketing of Lit-Control in the US by Diem Labs LLC 2019-05-03
AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO 2019-05-02
National Cancer Center (JP)–Fluidigm: mass cytometry, 201905 supply existent use of Hyperion Imaging System for I-O research 2019-05-02
Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson 2019-05-02
SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS 2019-04-30
SomaLogic–Agilent: oligo microarrays, 201904– supply €na multi-year custom oligo arrays for SOMAscan assay 2019-04-30
908 Devices–ARCH Venture: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor ARCH Ventures 2019-04-29
908 Devices–Casdin Capital: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Casdin Capital 2019-04-29
908 Devices–Northpond Ventures: investment, 201904 financing round Series E totalling $17.5m incl new + lead investor Northpond Ventures 2019-04-29
908 Devices–Razor’s Edge Ventures: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Razor’s Edge Ventures 2019-04-29
908 Devices–Sands Capital: investment, 201904 financing round Series E totalling $17.5m incl new + co-investor Sands Capital Ventures 2019-04-29
908 Devices–Saudi Arabia: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Saudi Aramco Energy Ventures 2019-04-29
908 Devices–Schlumberger: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Schlumberger 2019-04-29
908 Devices–SEVERAL: investment, 201904 financing round Series E $17.5m led by new investor Northpond Ventures 2019-04-29
908 Devices–Tao Capital Partners: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Tao Capital Partners 2019-04-29
Canopy Biosciences–Ampersand: investment, 201904 strategic growth investment from Ampersand Capital Partners 2019-04-29
JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen 2019-04-29
Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences 2019-04-29
ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development 2019-04-24
LabCorp–Biocartis: molecular diagnostics, 201904– collab ww €na offering of Idylla platform + oncology assays by Covance for drug development 2019-04-23
Sherlock Biosciences–Baidu Ventures: investment, 201903–201904 financing round Series A totalling $31m incl co-lead investor Baidu Ventures 2019-04-23
Sherlock Biosciences–Northpond Ventures: investment, 201903–201904 financing round Series A totalling $31m incl co-lead investor Northpond Ventures 2019-04-23
Sherlock Biosciences–Open Philanthropy Project: investment, 201903–201904 financing round Series A totalling $31m incl co-investor OPP 2019-04-23
DSM–Panacea BioMatx: nutripharmaceuticals, 201904– collab excl marketing + sales of personalised nutrition products of Panaceutics by DSM 2019-04-22
Poseida Therapeutics–Aisling Capital: investment, 201904 financing round Series C totalling $142m incl new + co-investor Aisling Capital Management 2019-04-22
Poseida Therapeutics–Canale Communications: public relations, 201904 service existent by Canale 2019-04-22
Poseida Therapeutics–Longitude Capital: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Longitude Capital 2019-04-22
Poseida Therapeutics–Malin Corp: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Malin Corp 2019-04-22
Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG 2019-04-22
Poseida Therapeutics–Pentwater Capital: investment, 201904 financing round Series C totalling $142m incl new + co-investor Pentwater Capital 2019-04-22
Poseida Therapeutics–Perceptive Advisors: investment, 201904 financing round Series C totalling $142m incl new + co-investor Perceptive Advisors 2019-04-22
Poseida Therapeutics–SEVERAL: investment, 201904 financing round Series C $142m led by Novartis with $75m 2019-04-22
Poseida Therapeutics–Tavistock: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Boxer Capital LLC 2019-04-22
Poseida Therapeutics–Vivo Capital: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Vivo Capital 2019-04-22
Arrakis Therapeutics–Advent Venture Partners: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Advent LS 2019-04-18
Arrakis Therapeutics–Alexandria Real Estate: investment, 201904 financing round Series B totalling $75m incl new + co- investor Alexandria Ventures 2019-04-18
Arrakis Therapeutics–Alphabet: investment, 201904 financing round Series B totalling $75m incl new + co- investor GV 2019-04-18
Arrakis Therapeutics–Canaan Partners: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Canaan Partners 2019-04-18
Arrakis Therapeutics–Celgene: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Celgene Corp 2019-04-18
Arrakis Therapeutics–HBM: investment, 201904 financing round Series B totalling $75m incl new + co- investor HBM Healthcare Investments 2019-04-18
Arrakis Therapeutics–Nextech Invest: investment, 201904 financing round Series B totalling $75m incl co-lead investor Nextech Invest 2019-04-18
Arrakis Therapeutics–Omega Advisors: investment, 201904 financing round Series B totalling $75m incl new + co- investor Omega Funds 2019-04-18
Arrakis Therapeutics–Osage Partners: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Osage University Partners 2019-04-18
Arrakis Therapeutics–PERSON: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Estate of Henri Termeer 2019-04-18
Arrakis Therapeutics–Pfizer: investment, 201904 financing round Series B totalling $75m incl existing + co- investor Pfizer Ventures 2019-04-18
Arrakis Therapeutics–SEVERAL: investment, 201904 financing round Series B $75m co-led by VenBio Partners + Nextech Invest 2019-04-18
Arrakis Therapeutics–VenBio: investment, 201904 financing round Series B totalling $75m incl co-lead investor VenBio Partners 2019-04-18
Arrakis Therapeutics–WuXi PharmaTech: investment, 201904 financing round Series B totalling $75m incl new + co- investor WuXi AppTec Venture Fund 2019-04-18
CytoSen Therapeutics–Kiadis: investment, 201904– acquisition merger in shares with 1.94m shares (7.4%) upfront plus 5.82 shares milestones 2019-04-17
Hookipa–Bank of America: financial services, 201904 supply service BofA Merrill Lynch is joint book-running manager for IPO 2019-04-17
Hookipa–RBC Capital Markets: financial services, 201904 supply service RBC Capital Markets is joint book-running manager for IPO 2019-04-17
Hookipa–Silicon Valley Bank: financial services, 201904 supply service SVP Leerink is joint book-running manager for IPO 2019-04-17
Hookipa–Van Lanschot: financial services, 201904 supply service Kempen is co-manager for IPO 2019-04-17
Bruker Corp–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML 2019-04-16
1 2 3 ... 61 62 63  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top